Department of Dermatology, University of Münster, Münster, Germany.
J Am Acad Dermatol. 2011 Dec;65(6):e179-93. doi: 10.1016/j.jaad.2010.06.018. Epub 2010 Aug 23.
In patients with cutaneous lupus erythematosus (CLE), it is important to provide instructions concerning methods of protection from sunlight and artificial sources of ultraviolet radiation. Topical corticosteroids are the mainstay of treatment for patients with CLE; however, they are of limited value because of their well-known side effects. Recently, calcineurin inhibitors have been shown to be efficient as topical therapy in various CLE subtypes. The first-line treatment for severe and widespread skin manifestations is antimalarials; hydroxychloroquine or chloroquine can each be combined with quinacrine in refractory CLE. Systemic steroids can be used additionally in exacerbations of the disease. In the first part of this review, recent information on topical and first-line systemic treatment is described in detail while providing the reader with up-to-date information on efficacy, side effects, and dosage for the various agents. In the second part, additional systemic agents for the treatment of CLE will be discussed.
在患有皮肤红斑狼疮（CLE）的患者中，提供有关保护皮肤免受阳光和人工紫外线辐射的方法的说明非常重要。局部皮质类固醇是治疗 CLE 患者的主要方法；然而，由于其众所周知的副作用，它们的价值有限。最近，钙调神经磷酸酶抑制剂已被证明在各种 CLE 亚型中作为局部治疗有效。对于严重和广泛的皮肤表现，一线治疗是抗疟药；羟氯喹或氯喹均可与奎纳克林联合用于难治性 CLE。在疾病发作时可额外使用全身性类固醇。在这篇综述的第一部分中，详细描述了最近关于局部和一线全身治疗的信息，同时为读者提供了关于各种药物的疗效、副作用和剂量的最新信息。在第二部分中，将讨论其他用于治疗 CLE 的全身性药物。
